MedAdvisor Limited (AHE) AI Stock Analysis

• Market Cap: AU$11.46M
• Dividend Yield: N/A
• Average Volume (3M): 1.73M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.98
• Revenue Growth: -48.41%
• EPS Growth: -7200.00%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.11
• Shares Outstanding: 636,521,550
• 10 Day Avg. Volume: 474,818
• 30 Day Avg. Volume: 1,728,714
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: AU$0.02

The score is held down primarily by weak financial performance (sharp revenue decline, heavy losses, and negative equity). Technicals also remain bearish with the stock trading below major moving averages and a negative MACD, partially offset by an oversold RSI. Valuation provides limited support due to a negative P/E and no dividend.

Positive Factors

Recurring subscription and partnership revenue

A subscription-based model plus pharma and pharmacy partnerships create recurring, contractable revenue and diversify income streams. This structural mix supports predictable cash inflows, higher customer stickiness and long-term monetisation of patient engagement and data analytics capabilities.

Improving free cash flow growth

Positive free cash flow growth indicates improving cash conversion dynamics even amid losses. Sustained FCF improvement can reduce reliance on external funding, permit targeted reinvestment in product and partnerships, and materially improve financial flexibility over the next several quarters.

Positive return on equity despite capital strain

A positive ROE, even from a stressed capital base, signals management can extract economic value from invested capital. If maintained, this operational efficiency supports recovery prospects and indicates the core platform can generate returns as revenue stabilises and fixed-cost leverage improves.

Negative Factors

Sharp revenue decline

A nearly 40% revenue decline materially reduces scale and weakens unit economics, impairing the subscription model and partner monetisation. Persistent top-line contraction limits margin recovery, reduces pricing power with pharmacies/pharma, and makes sustainable profitability more difficult over months.

Precarious balance sheet and negative equity

Negative equity and extreme debt-to-equity indicate accumulated losses and constrained solvency. This structural weakness reduces borrowing capacity, limits strategic investments, raises refinancing risk, and constrains ability to pursue growth or withstand further revenue pressure in the medium term.

Deep losses and negative operating cash flow

Severe negative margins and ongoing negative operating cash flow erode internal funding ability and require external capital or drastic cost restructuring. Over 2–6 months this undermines investment in product and client retention, and increases execution risk for any recovery plans.

MedAdvisor Limited Business Overview & Revenue Model

Company Description

MedAdvisor Limited, together with its subsidiaries, develops and delivers software in Australia, the United States, the United Kingdom, and Asia. The company provides MedAdvisor, a medication and adherence platform that focuses on improving health outcomes by connecting health professionals with their patients using technology and enhancing medication adherence through health programs; THRiV, an intelligent digital adherence solution; and GuildCare, a cloud-based platform that offers healthcare solutions and medicines information for consumers, health professionals, and other partners. MedAdvisor Limited was incorporated in 2010 and is headquartered in Camberwell, Australia.

How the Company Makes Money

MedAdvisor generates revenue primarily through subscription fees from its digital health platform, which pharmacies and patients use to manage medications effectively. The company also earns money through partnerships with pharmaceutical manufacturers, where they offer targeted patient engagement services and promotional activities. Key revenue streams include fees from pharmacies for access to the platform, transaction fees for the sale of medications through its network, and income from data analytics services provided to healthcare stakeholders. These partnerships and services are crucial in driving the company's earnings and expanding its market presence.

MedAdvisor Limited Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

MedAdvisor Limited Technical Analysis

• Last Price: ―

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AHE, the sentiment is undefined. The current price of undefined is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for AU:AHE.

MedAdvisor Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%